These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 3385720)

  • 61. Determination of the anti-Alzheimer's disease drugs tacrine, 7-methoxytacrine, and its metabolites by capillary zone electrophoresis.
    Vargas MG; Havel J; Patocka J
    Am Clin Lab; 1998 Jun; 17(5):22-3. PubMed ID: 10181004
    [No Abstract]   [Full Text] [Related]  

  • 62. [9-amino-7-methoxy-1,2,3,4-tetrahydroacridine, a new substance with indirect cholinomimetic effects].
    Patocka J
    Cesk Farm; 1990 Feb; 39(1):29-32. PubMed ID: 2379246
    [No Abstract]   [Full Text] [Related]  

  • 63. Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates.
    Fang L; Appenroth D; Decker M; Kiehntopf M; Roegler C; Deufel T; Fleck C; Peng S; Zhang Y; Lehmann J
    J Med Chem; 2008 Feb; 51(4):713-6. PubMed ID: 18232655
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Substituted Aminobenzothiazole Derivatives of Tacrine: Synthesis and Study on Learning and Memory Impairment in Scopolamine-Induced Model of Amnesia in Rat.
    Ahmadi A; Roghani M; Noori S; Nahri-Niknafs B
    Mini Rev Med Chem; 2019; 19(1):72-78. PubMed ID: 30009706
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Novel tacrine-1,2,3-triazole hybrids: In vitro, in vivo biological evaluation and docking study of cholinesterase inhibitors.
    Najafi Z; Mahdavi M; Saeedi M; Karimpour-Razkenari E; Asatouri R; Vafadarnejad F; Moghadam FH; Khanavi M; Sharifzadeh M; Akbarzadeh T
    Eur J Med Chem; 2017 Jan; 125():1200-1212. PubMed ID: 27863370
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of tacrine, velnacrine (HP029), suronacrine (HP128), and 3,4-diaminopyridine on skeletal neuromuscular transmission in vitro.
    Braga MF; Harvey AL; Rowan EG
    Br J Pharmacol; 1991 Apr; 102(4):909-15. PubMed ID: 1649660
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Alzheimer's disease: how to give and monitor tacrine therapy.
    Woo JK; Lantz MS
    Geriatrics; 1995 May; 50(5):50-3. PubMed ID: 7737527
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [The cholinergic perspectives in the treatment of Alzheimer's disease: tacrine].
    Royuela Rico A; Macías Fernández JA
    Rev Clin Esp; 1995 Jul; 195(7):473-8. PubMed ID: 7667523
    [No Abstract]   [Full Text] [Related]  

  • 69. Galantamine: new preparation. The fourth cholinesterase inhibitor for Alzheimer's disease.
    Prescrire Int; 2001 Dec; 10(56):180-1. PubMed ID: 11824442
    [TBL] [Abstract][Full Text] [Related]  

  • 70. New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer's disease, with cholinergic, antioxidant, and β-amyloid-reducing properties.
    Fernández-Bachiller MI; Pérez C; Monjas L; Rademann J; Rodríguez-Franco MI
    J Med Chem; 2012 Feb; 55(3):1303-17. PubMed ID: 22243648
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cholinesterase inhibition in the scopolamine model of dementia.
    Wesnes KA; Simpson PM; White L; Pinker S; Jertz G; Murphy M; Siegfried K
    Ann N Y Acad Sci; 1991; 640():268-71. PubMed ID: 1776749
    [TBL] [Abstract][Full Text] [Related]  

  • 72. WITHDRAWN: Tacrine for Alzheimer's disease.
    Qizilbash N; Birks J; Lopez Arrieta J; Lewington S; Szeto S
    Cochrane Database Syst Rev; 2007 Jul; (3):CD000202. PubMed ID: 17636619
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Initial experience with the administration of 7-methoxyacrine to patients with psychological disorders].
    Zapletálek M; Hanus H; Fusek J; Hrdina V
    Cesk Psychiatr; 1989 Jun; 85(3):155-8. PubMed ID: 2766394
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Design, synthesis, and molecular-modeling study of aminothienopyridine analogues of tacrine for Alzheimer's disease.
    Badran MM; Abdel Hakeem M; Abuel-Maaty SM; El-Malah A; Abdel Salam RM
    Arch Pharm (Weinheim); 2010 Oct; 343(10):590-601. PubMed ID: 20925094
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Bis(7)-tacrine, a promising anti-Alzheimer's agent, reduces hydrogen peroxide-induced injury in rat pheochromocytoma cells: comparison with tacrine.
    Xiao XQ; Lee NT; Carlier PR; Pang Y; Han YF
    Neurosci Lett; 2000 Sep; 290(3):197-200. PubMed ID: 10963897
    [TBL] [Abstract][Full Text] [Related]  

  • 76. New drugs for Alzheimer's disease in Japan.
    Takeda M; Tanaka T; Okochi M
    Psychiatry Clin Neurosci; 2011 Aug; 65(5):399-404. PubMed ID: 21851448
    [No Abstract]   [Full Text] [Related]  

  • 77. From mechanisms to drugs in Alzheimer's disease.
    Fricker J
    Lancet; 1997 Feb; 349(9050):480. PubMed ID: 9053700
    [No Abstract]   [Full Text] [Related]  

  • 78. Progress report on the Canadian Multicentre Trial of tetrahydroaminoacridine with lecithin in Alzheimer's disease.
    Gauthier S; Bouchard R; Bacher Y; Bailey P; Bergman H; Carrier L; Charbonneau R; Clarfield M; Collier B; Dastoor D
    Can J Neurol Sci; 1989 Nov; 16(4 Suppl):543-6. PubMed ID: 2680009
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Tacrine therapy for the dementia of Alzheimer's disease.
    Manning FC
    Am Fam Physician; 1994 Sep; 50(4):819-26. PubMed ID: 8079912
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Evaluation of HP 029 (velnacrine maleate) in Alzheimer's disease.
    Murphy MF; Hardiman ST; Nash RJ; Huff FJ; Demkovich JJ; Dobson C; Knappe UE
    Ann N Y Acad Sci; 1991; 640():253-62. PubMed ID: 1776747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.